Vaxinano is a pioneering biotech company focused on developing prophylactic and therapeutic nasal vaccines. The company is advancing its flagship vaccines and immuno-therapies targeting diseases such as leishmaniasis, toxoplasmosis, and colibacillosis into clinical trials.
Leadership & Board
Current Number of Employees13
Current LinkedIn Followers1,788
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$6M
Total Amount Raised$6M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$6M
Latest Funding Amount$6M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Vaxinano had 13 employees as of April 6, 2026. The number of employees decreased by 1 (7.14%) week-over-week.
13Latest Employee Count
1(-7.14%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Vaxinano had 1,788 followers as of April 6, 2026. The number of followers increased by 2 (0.11%) week-over-week.
1,788Latest Followers Count
2(0.11%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.